Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation.

By combining treatment groups, survival analysis according to pathologic response (pCR n = 68; RD n = 88) revealed a highly significant association between pCR and D-DFS, with 4-year D-DFS 93.6% vs 70.9% for pCR vs no-pCR, respectively (HR = 0.26, 95% CI 0.10–0.69, P = 0.007), as shown in Fig. 3 .

also in 132,142 other papers

TIL levels significantly increased from baseline to matched RD in the overall population and in both A-TCb and AT treatment groups (with an association of borderline significance in the AT cohort), as shown in Fig. 4a .

also in 2,624 other papers